FDA
-
-
-
-
-
-
-
Agios halts tebapivat development for blood cancer indication
-
-
-
-
-
-
-
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
-
-
-
-
-
-
-
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Raised to $62 at H.C. Wainwright
-
-
-
-
-
-
-
Leerink Partners Upgrades Agios Pharma (AGIO) to Outperform
-
-
-
-
-
-
-
Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia
-
-
-
-
-
-
-
Agios Pharma (AGIO) PT Raised to $52 at BofA Securities
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

